Drug Profile
Agenmestencel-T
Alternative Names: MSC-apceth-101Latest Information Update: 06 Jan 2021
Price :
$50
*
At a glance
- Originator Apceth
- Developer Minaris Regenerative Medicine
- Class Gene therapies; Immunotherapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements; Gene transference; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Gastrointestinal cancer
Most Recent Events
- 14 Jun 2019 Apceth completes the TREAT-ME 1 phase I/II trial in Gastrointestinal cancer (Late-stage disease, Metastatic disease) in Germany (NCT02008539)
- 31 May 2019 Final efficacy and adverse events data from a the phase-I/II trial TREAT-ME 1 trial in Gastrointestinal cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
- 11 Sep 2017 Agenmestencel-T is still in phase II development for Gastrointestinal cancer (Late-stage disease, Metastatic disease) in Germany (Apceth pipeline, September 2017)